FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 7

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Feb 21, 2015; 21(7): 2096-2101
Published online Feb 21, 2015. doi: 10.3748/wjg.v21.i7.2096

Table 2 Observed toxicity according National Cancer Institute Common Terminology Criteria for adverse events grading (n = 12)

¹Grade 3-4 according to the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTC) version 2.0 scale.

Citation: Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21(7): 2096-2101
URL: https://www.wjgnet.com/1007-9327/full/v21/i7/2096.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i7.2096

Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21(7): 2096-2101 [PMID: 25717243 DOI: 10.3748/wjg.v21.i7.2096]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.